Phase II Trial of Gemcitabine/Doxorubicin/Paclitaxel Administered Every Other Week in Patients with Metastatic Breast Cancer
Authors:
- Pedro Sánchez-RoviraPSPedro Sánchez-Rovira
- Ana JaénAJAna Jaén
- Encarnación GonzálezEGEncarnación González
- Ignacio PorrasIPIgnacio Porras
- Maria Rosario DueñasMDMaria Rosario Dueñas
- Begoña MedinaBMBegoña Medina
- Nicolás MohedanoNMNicolás Mohedano
- Margarita FernándezMFMargarita Fernández
- Maximiliano MartosMMMaximiliano Martos
- Ana LozanoALAna Lozano
- 1 October 2000
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 1 (3) , 226-232
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic TrialJournal of Clinical Oncology, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumorsAnnals of Oncology, 1998
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology, 1997
- 685: Preliminary results from an early phase II combination of gemcitabine and taxol in metastatic breast cancerEuropean Journal of Cancer, 1997
- GemcitabineDrugs, 1997
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.Journal of Clinical Oncology, 1997
- Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1997
- Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995